Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the year ending March 31, 2024. For the year, the company revised revenue of JPY 317,000 million compared to previous guidance of JPY 362,000 million. Core operating loss of JPY 134,000 million compared to previous guidance of JPY 62,000 million.

Operating loss of JPY 156,000 million compared to previous guidance of JPY 78,000 million. Net loss attributable to owners of the parent of JPY 141,000 million compared to previous guidance of JPY 80,000 million and basic loss per share of JPY 354.90 compared to previous guidance of JPY 201.36.